Therapeutic Advances in Hematology (TAH)

Therapeutic Advances in Hematology is an international, peer-reviewed, fully Gold Open Access journal published by SAGE Publishing. Established in 2010, the journal focuses on the latest therapeutic developments, clinical research, and evidence-based advances in the diagnosis and treatment of hematological disorders. It serves as a valuable resource for hematologists, oncologists, transfusion medicine specialists, clinical researchers, pharmacists, and healthcare professionals involved in the management of blood diseases. The journal publishes original research articles, systematic reviews, narrative reviews, meta-analyses, clinical trials, case reports, editorials, and expert perspectives covering both malignant and non-malignant hematological conditions. Major topics include leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, anemia, hemophilia, thrombosis, coagulation disorders, stem cell transplantation, immunotherapy, targeted therapies, gene therapy, and precision medicine. The journal particularly emphasizes clinically relevant research that can improve patient care and therapeutic outcomes. All manuscripts undergo rigorous peer review to ensure scientific quality, originality, and clinical relevance. The journal is indexed in major databases including PubMed, PubMed Central, Scopus, and Science Citation Index Expanded (SCIE), providing broad international visibility. As a fully open-access journal, all accepted articles are freely accessible worldwide immediately upon publication, promoting rapid dissemination of advances in hematology.

Therapeutic Advances in Hematology (TAH) is :-

• International, Peer-Reviewed, Open Access, Refereed, Hematology, Clinical Hematology, Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Coagulation Disorders, Transfusion Medicine, Stem Cell Transplantation, Targeted and Precision Therapies, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, anemia, hemophilia, thrombosis, coagulation disorders, stem cell transplantation, immunotherapy, targeted therapies, gene therapy, precision medicine , Online or Print , Continuously Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 2040-6207, E-ISSN: 2040-6215, Established: 2010,
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE